Literature DB >> 15543590

Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.

Hideki Hasegawa1, Takeshi Ichinohe, Peter Strong, Izumi Watanabe, Satoshi Ito, Shin-Ichi Tamura, Hidehiro Takahashi, Hirofumi Sawa, Joe Chiba, Takeshi Kurata, Tetsutaro Sata.   

Abstract

Chitin in the form of microparticles (chitin microparticles, CMP) has been demonstrated to be a potent stimulator of macrophages, promoting T-helper-1 (Th1) activation and cytokine response. In order to examine the mucosal adjuvant effect of CMP co-administered with influenza hemagglutinin (HA) vaccine against influenza infection, CMP were intranasally co-administered with influenza HA vaccine prepared from PR8 (H1N1) virus. Inoculation of the vaccine with CMP induced primary and secondary anti-HA IgA responses in the nasal wash and anti-HA IgG responses in the serum, which were significantly higher than those of nasal vaccination without CMP, and provided a complete protection against a homologous influenza virus challenge in the nasal infection influenza model. In addition, CMP-based immunization using A/Yamagata (H1N1) and A/Guizhou (H3N2) induced PR8 HA-reactive IgA in the nasal washes and specific-IgG in the serum. The immunization with A/Yamagata and CMP resulted in complete protection against a PR8 (H1N1) challenge in A/Yamagata (H1N1)-vaccinated mice, while that with A/Guizhou (H3N2) and CMP exhibited a 100-fold reduction of nasal virus titer, demonstrating the cross-protective effect of CMP and influenza vaccine. It is suggested that CMP provide a safe and effective adjuvant for nasal vaccination with inactivated influenza vaccine. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15543590     DOI: 10.1002/jmv.20247

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  Vaccination with Killed but Metabolically Active E. coli Over-expressing Hemagglutinin Elicits Neutralizing Antibodies to H1N1 Swine Origin Influenza A Virus.

Authors:  Pei-Feng Liu; Yanhan Wang; Yu-Tsueng Liu; Chun-Ming Huang
Journal:  J Nat Sci       Date:  2017-02

Review 2.  Novel vaccine development strategies for inducing mucosal immunity.

Authors:  Yoshiko Fujkuyama; Daisuke Tokuhara; Kosuke Kataoka; Rebekah S Gilbert; Jerry R McGhee; Yoshikazu Yuki; Hiroshi Kiyono; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2012-03       Impact factor: 5.217

Review 3.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

4.  Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia.

Authors:  Ho Namkoong; Makoto Ishii; Hideki Fujii; Kazuma Yagi; Takahiro Asami; Takanori Asakura; Shoji Suzuki; Ahmed E Hegab; Hirofumi Kamata; Sadatomo Tasaka; Koji Atarashi; Nobuhiro Nakamoto; Satoshi Iwata; Kenya Honda; Takanori Kanai; Naoki Hasegawa; Shigeo Koyasu; Tomoko Betsuyaku
Journal:  PLoS Pathog       Date:  2018-04-05       Impact factor: 6.823

5.  Induction of Protection in Mice against a Chlamydia muridarum Respiratory Challenge by a Vaccine Formulated with the Major Outer Membrane Protein in Nanolipoprotein Particles.

Authors:  Delia F Tifrea; Wei He; Sukumar Pal; Angela C Evans; Sean F Gilmore; Nicholas O Fischer; Amy Rasley; Matthew A Coleman; Luis M de la Maza
Journal:  Vaccines (Basel)       Date:  2021-07-07

6.  Intranasal administration of immunogenic poly-epitope from influenza H1N1 and H3N2 viruses adjuvanted with chitin and chitosan microparticles in BALB/c mice.

Authors:  Sahar Sadeghi; Mojgan Bandehpour; Mostafa Haji Molla Hoseini; Zarin Sharifnia
Journal:  Iran J Basic Med Sci       Date:  2021-08       Impact factor: 2.699

7.  Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses.

Authors:  Hideki Hasegawa; Takeshi Ichinohe; Akira Ainai; Shin-Ichi Tamura; Takeshi Kurata
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

8.  Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100.

Authors:  Heng Liu; Harshad P Patil; Jacqueline de Vries-Idema; Jan Wilschut; Anke Huckriede
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

Review 9.  An Overview of Challenges Limiting the Design of Protective Mucosal Vaccines for Finfish.

Authors:  Hetron Mweemba Munang'andu; Stephen Mutoloki; Øystein Evensen
Journal:  Front Immunol       Date:  2015-10-22       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.